Advances in immunotherapy of extranodal NK/T cell lymphoma
10.3760/cma.j.issn.1673-0860.2019.12.015
- VernacularTitle: 结外NK/T细胞淋巴瘤免疫治疗的研究进展
- Author:
Dingqian HAO
1
;
Lianqing LI
2
;
Maocai LI
2
;
Lili GONG
2
Author Information
1. Shandong First Medical University (Shandong Academy of Medical Sciences), Taian 271000, China
2. Liaocheng People′s Hospital, Otorhinolaryngology Head and Neck Surgery, Liaocheng 252000, China
- Publication Type:Review
- Keywords:
Lymphoma, extranodal NK-T-cell;
Immunotherapy;
PD1/PDL1;
CTLA-4;
EBV-associated antigen;
CD30;
CD38
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2019;54(12):949-953
- CountryChina
- Language:Chinese
-
Abstract:
Extranodal NK/T-cell lymphoma (ENKTCL) is a relatively rare group of highly aggressive non-Hodgkin′s lymphoma (NHL). The disease has rapid clinical progress, high degree of malignancy and poor prognosis. Traditional chemoradiotherapy regimens have not shown good efficacy. In recent years, the immunotherapy of tumors has developed rapidly. At present, it has shown strong therapeutic activity in the treatment of various solid tumors such as non-small cell lung cancer, prostate cancer, melanoma and kidney cancer. Multiple tumor immunotherapy drugs have been approved by the US Food and Drug Administration (FDA) for clinical use. This article reviews recent novel immunotherapeutic regimens of ENKTCL, hoping to change the treatment modality of this malignant disease.
